RepHorm
A device that will dramatically improve the protection of babies during birth. It will monitor the child continuously with better acuity, resulting in better clinical outcomes at a lower cost.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0RepHorm project word cloud
Explore the words cloud of the RepHorm project. It provides you a very rough idea of what is the project "RepHorm" about.
Project "RepHorm" data sheet
The following table provides information about the project.
| Coordinator |
BLUEBRIDGE TECHNOLOGIES LTD
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | http://bluebridgetechnologies.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2014 |
| Funding Scheme | SME-1 |
| Starting year | 2014 |
| Duration (year-month-day) | from 2014-10-01 to 2015-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | BLUEBRIDGE TECHNOLOGIES LTD | IE (DUBLIN) | coordinator | 50˙000.00 |
Map
Project objective
The objective of this Phase 1 application is a feasibility study to assess the commercial viability of RepHorM, and quantify the business opportunity. This project is to develop a real-time in vivo infant monitor that safe guards the baby during birth. This achieved with a fiber optic based biomarker sensor. This device will for the first time provide doctors with a real-time, continuous and objective measure of a baby’s health during labour by incorporating this technology into an existing medical device. The learning curve will be small in taking up the new device and the specific biomarker, is very familiar to obstetricians as well as other clinicians, and the threshold levels for intervention are already established. This Innovative solution uses latest technology deployed to an old, long standing problem. The research into the sensor chemistry has been now completed and this activity has moved the technology form TRL 3 to the current TRL 6. The worldwide market for monitoring was €6.2 Billion in 2010 and is predicted to increase by 4.4% compound annual growth rate (CAGR) to reach € 8 Billion in 2016. None of the current methods offer clear advantages over one another. The general trend in medicine is towards individual bedside or in-patient testing of key biomarkers, in particular, there is a trend towards continuous bio-diagnostics. BlueBridge Technologies hope to use Phase 1 to identify obstacles to successful product development and launch, and develop solutions to manage them. The work will then serve to better understand and describe exactly what type of product(s) the market requires and subsequently estimate the development costs, time to Market and provide the inputs needed for a Phase 2 application.
Babies and the market need this product as they are currently under served by the current offerings and we passionately want to lead the response to this noble call.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REPHORM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "REPHORM" are provided by the European Opendata Portal: CORDIS opendata.